The DOI matches its Crossref record.
Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use
Abstract
Summary s-1 1 introduction 1-1 PART I Pain management and research 2 Pain management and the intersection of pain and opioid use disorder 2-1 • The scope of the problem of pain, 2-1 • Opioid analgesics, 2-4 • Nonopioid pharmacologic treatments, 2-16 • Interventional pain therapies, 2-25 • Nonpharmacologic treatments, 2-27 • Differences in pain experiences and treatment effectiveness among • Subpopulations, 2-33 • The intersection between pain and opioid use disorder, 2-36 • References, 2-36 3 Progress and future directions in research on pain and opioid use disorder 3-1 • Basic pain research, 3-1 • The neurobiology of the reward pathway and the intersection of pain and opioid • Use disorder, 3-10 • Preclinical and translational research, 3-13 • Clinical research, 3-18 • Intersection of pain and opioid use disorder, 3-26 • Support for research, 3-33 • Summary and recommendation, 3-34 • References, 3-34 PART II Addressing the opioid epidemic 4 Trends in opioid use, harms, and treatment 4-1 • Trends in prescription opioid use and misuse, 4-1 • Heroin use and its relation to prescription opioid use, 4-15 • Illicit opioid markets, 4-25 • The current state of surveillance systems, 4-32 • Recent developments in pharmaceutical treatment of opioid use disorder, 4-35 • Trends in treatment of opioid overdose with naloxone, 4-46 • Summary and recommendations, 4-48 • References, 4-49 5 Evidence on strategies for addressing the opioid epidemic 5-1 • Nature of the Evidence, 5-2 • The Need for a Systems Approach, 5-4 • Strategies for Restricting Supply, 5-10 • Strategies for Influencing Prescribing Practices, 5-21 • Strategies for Reducing Demand, 5-39 • Strategies for Reducing Harm, 5-46 • Summary and Recommendations, 5-58 • References, 5-60 6 Opioid approval and monitoring by the U.S. Food and drug administration 6-1 • Overview of the FDA’s regulatory process for prescription drugs and its application to opioids, 6-2 • Public health dimensions of FDA drug regulation, 6-17 • Key elements of an integrated decision-making framework for opioid • Regulation,6-22 • Implementation of an integrated framework for opioid regulation, 6-25 • Summary and recommendations, 6-40 • References, 6-44 • Annex table 6-1: extended-release(er)/long-acting (la) opioid post-marketing • Study requirements, 6-49 Appendixes A Data sources and methods a-1 B Biographical sketches of committee members and consultants b-1 C Existing data sources on opioid use, misuse, overdose, and other harms c-1 [Note: Download from NAP site if free, but may require guest registration with your email.]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Knaul, F. M., Farmer, P. E., Krakauer, E. L., De Lima, L., Bhadelia, A., Jiang Kwete, X., Arreola-Ornelas, H., Gómez-Dantés, O., Rodriguez, N. M., Alleyne, G. A. O., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32513-8 · Cited by 1,456
Opioid crisis: no easy fix to its social and economic determinants
Dasgupta, N., Beletsky, L., & Ciccarone, D. (2018) · American Journal of Public Health · doi:10.2105/ajph.2017.304187 · Cited by 923
Management of Musculoskeletal Pain: An Update with Emphasis on Chronic Musculoskeletal Pain
El-Tallawy, S. N., Nalamasu, R., Salem, G. I., LeQuang, J. A. K., Pergolizzi, J. V., & Christo, P. J. (2021) · Pain and Therapy · doi:10.1007/s40122-021-00235-2 · Cited by 532
Evidence-Based Nonpharmacologic Strategies for Comprehensive Pain Care
Tick, H., Nielsen, A., Pelletier, K. R., Bonakdar, R., Simmons, S., Glick, R., Ratner, E., Lemmon, R. L., Wayne, P., & Zador, V. (2018) · EXPLORE · doi:10.1016/j.explore.2018.02.001 · Cited by 380
Fentanyl shock: The changing geography of overdose in the United States
Zoorob, M. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.04.010 · Cited by 160
Niknejad, B., Bolier, R., Henderson, C. R., Delgado, D., Kozlov, E., Löckenhoff, C. E., & Reid, M. C. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0756 · Cited by 152
Azuine, R. E., Ji, Y., Chang, H.-Y., Kim, Y., Ji, H., DiBari, J., Hong, X., Wang, G., Singh, G. K., Pearson, C., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.6405 · Cited by 152
Trends and Rapidity of Dose Tapering Among Patients Prescribed Long-term Opioid Therapy, 2008-2017
Fenton, J. J., Agnoli, A. L., Xing, G., Hang, L., Altan, A. E., Tancredi, D. J., Jerant, A., & Magnan, E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.16271 · Cited by 97
Bechara, A., Berridge, K. C., Bickel, W. K., Morón, J. A., Williams, S. B., & Stein, J. S. (2019) · Psychological Science in the Public Interest · doi:10.1177/1529100619860513 · Cited by 82
Aytur, S. A., Ray, K. L., Meier, S. K., Campbell, J., Gendron, B., Waller, N., & Robin, D. A. (2020) · doi:10.1101/2020.08.10.20144063 · Cited by 49
Kakko, J., Gedeon, C., Sandell, M., Grelz, H., Birkemose, I., Clausen, T., Rúnarsdóttir, V., Simojoki, K., Littlewood, R., Alho, H., et al. (2018) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-018-0160-7 · Cited by 10
Metadata
- Authors
- Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse, Board on Health Sciences Policy, Division, H. A. M., & National Academies of Sciences, E.
- Venue
- National Academies Press eBooks
- Publisher
- National Academies Press
- Published
- 2017-09-28
- OpenAlex
- W2734333671
- Cited by
- 229
- References
- 0
- FWCI
- 46.87
- Type
- book
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.